Lunai Bioworks to Voluntarily Delist From Nasdaq After Equity Failure
LNAI is trading near its 52-week low of $0.46 (17% below the low).
Summary
Lunai received a Nasdaq delisting determination after failing the exchange's $2.5M minimum stockholders' equity requirement — the company reported a stockholders' deficit of $9.02M as of June 30, 2026. Trading is expected to be suspended at the open on October 30, 2026, with a Form 25 filing around November 2 and the delisting effective around November 12. This follows the October 9 8-K in which Lunai asked Nasdaq to immediately suspend trading, citing alleged short-selling abuses, and the October 13 10-K that disclosed less than one month of cash runway, a going concern warning, a material weakness and a Nasdaq equity deficit. The stock already trades near its 52-week low at a fraction of last year's levels, and losing the Nasdaq listing strips the shares of exchange liquidity and institutional eligibility. The 13D/A on October 16 showed Wittekind's stake falling to 4.5%, crossing below the 5% threshold.
At the time of this announcement, LNAI was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.46 to $13.28. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Seeking Alpha.